+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Preparation, in vitro and in vivo evaluation of mPEG-PLGA nanoparticles co-loaded with syringopicroside and hydroxytyrosol



Preparation, in vitro and in vivo evaluation of mPEG-PLGA nanoparticles co-loaded with syringopicroside and hydroxytyrosol



Journal of Materials Science. Materials in Medicine 27(2): 24



This study investigated the therapeutic efficiency of monomethoxy polyethylene glycol-poly(lactic-co-glycolic acid) (mPEG-PLGA) co-loaded with syringopicroside and hydroxytyrosol as a drug with effective targeting and loading capacity as well as persistent circulation in vivo. The nanoparticles were prepared using a nanoprecipitation method with mPEG-PLGA as nano-carrier co-loaded with syringopicroside and hydroxytyrosol (SH-NPs). The parameters like in vivo pharmacokinetics, biodistribution in vivo, fluorescence in vivo endomicroscopy, and cellular uptake of SH-NPs were investigated. Results showed that the total encapsulation efficiency was 32.38 ± 2.76 %. Total drug loading was 12.01 ± 0.42 %, particle size was 91.70 ± 2.11 nm, polydispersity index was 0.22 ± 0.01, and zeta potential was -24.5 ± 1.16 mV for the optimized SH-NPs. The nanoparticle morphology was characterized using transmission electron microscopy, which indicated that the particles of SH-NPs were in uniformity within the nanosize range and of spherical core shell morphology. Drug release followed Higuchi kinetics. Compared with syringopicroside and hydroxytyrosol mixture (SH), SH-NPs produced drug concentrations that persisted for a significantly longer time in plasma following second-order kinetics. The nanoparticles moved gradually into the cell, thereby increasing the quantity. ALT, AST, and MDA levels were significantly lower on exposure to SH-NPs than in controls. SH-NPs could inhibit the proliferation of HepG2.2.15 cells and could be taken up by HepG2.2.15 cells. The results confirmed that syringopicroside and hydroxytyrosol can be loaded simultaneously into mPEG-PLGA nanoparticles. Using mPEG-PLGA as nano-carrier, sustained release, high distribution in the liver, and protective effects against hepatic injury were observed in comparison to SH.

(PDF emailed within 0-6 h: $19.90)

Accession: 058609186

Download citation: RISBibTeXText

PMID: 26704541

DOI: 10.1007/s10856-015-5641-x


Related references

Preparation of DHAQ-loaded mPEG-PLGA-mPEG nanoparticles and evaluation of drug release behaviors in vitro/in vivo. Journal of Materials Science. Materials in Medicine 17(6): 509-516, 2006

In-vitro evaluation of paclitaxel-loaded MPEG-PLGA nanoparticles on laryngeal cancer cells. Anti-Cancer Drugs 20(9): 807-814, 2010

Preparation, characterization and in vivo distribution of solid lipid nanoparticles loaded with syringopicroside. Die Pharmazie 66(6): 404-407, 2011

In vivo investigation of tolerance and antitumor activity of cisplatin-loaded PLGA-mPEG nanoparticles. European Journal of Pharmaceutics and Biopharmaceutics 71(2): 190-195, 2008

Bufalin-loaded mPEG-PLGA-PLL-cRGD nanoparticles: preparation, cellular uptake, tissue distribution, and anticancer activity. International Journal of Nanomedicine 7: 3961-3969, 2013

Preparation and in vitro evaluation of thienorphine-loaded PLGA nanoparticles. Drug Delivery 23(3): 787-793, 2016

Effect of preparation conditions on the size and encapsulation properties of mPEG-PLGA nanoparticles simultaneously loaded with vincristine sulfate and curcumin. Pharmaceutical Development and Technology 18(3): 694-700, 2013

Endostar-loaded PEG-PLGA nanoparticles: in vitro and in vivo evaluation. International Journal of Nanomedicine 5: 1039-1048, 2011

Preparation, Characterization and In Vivo Evaluation of pH-sensitive Oral Insulin-Loaded PLGA Nanoparticles. 2011

Doxorubicin-loaded PLGA nanoparticles by nanoprecipitation: preparation, characterization and in vitro evaluation. Nanomedicine 2(2): 219-232, 2007

Preparation and in vivo evaluation of insulin-loaded biodegradable nanoparticles prepared from diblock copolymers of PLGA and PEG. International Journal of Pharmaceutics 499(1-2): 236-246, 2016

A co-delivery system based on paclitaxel grafted mPEG-b-PLG loaded with doxorubicin: preparation, in vitro and in vivo evaluation. International Journal of Pharmaceutics 471(1-2): 412-420, 2015

Preparation and in vitro evaluation of tetrandrine-loaded composite microspheres embedded with PLGA nanoparticles. Zhongguo Zhong Yao Za Zhi 41(5): 838-844, 2016

Paclitaxel-loaded PEGylated PLGA-based nanoparticles: in vitro and in vivo evaluation. Journal of Controlled Release 133(1): 11-17, 2008

Preparation of sustained release apremilast-loaded PLGA nanoparticles: in vitro characterization and in vivo pharmacokinetic study in rats. International Journal of Nanomedicine 14: 1587-1595, 2019